计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G646178-2mg |
2mg |
期货 ![]() |
| |
| G646178-5mg |
5mg |
期货 ![]() |
| |
| G646178-10mg |
10mg |
期货 ![]() |
| |
| G646178-25mg |
25mg |
期货 ![]() |
| |
| G646178-50mg |
50mg |
期货 ![]() |
| |
| G646178-100mg |
100mg |
期货 ![]() |
|
| 规格或纯度 | ≥99% |
|---|---|
| 英文名称 | GSK864 |
| 生化机理 | GSK864 是一种异柠檬酸脱氢酶 1(IDH1)突变体抑制剂;可抑制 IDH1 突变体 R132C、R132H 和 R132G,IC 50 值分别为 8.8、15.2 和 16.6 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
GSK864 is an isocitrate dehydrogenase 1 ( IDH1 ) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC 50 values of 8.8, 15.2 and 16.6 nM. In Vitro GSK864 inhibits 2-HG production in R132C IDH1 mutant HT1080 fibrosarcoma cells with an EC 50 of 320 nM by LCMS/MS analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Following intraperitoneal (IP) administration in CD-1 mice, significant concentrations of GSK864 are maintained in peripheral blood samples of mice for up to 24 hours. Analysis of BM cells for expression of markers of early differentiation reveals slightly increased numbers of huCD45 + CD38 + cells in R132C or R132H IDH1 mutant engrafted mice treated with GSK864 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 8.8 nM (IDH1 mutants R132C), 15.2 nM (IDH1 mutants R132H), 16.6 nM (IDH1 mutants R132G) |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 未知 |
|---|---|
| IIUPAC Name | (7S)-1-[(4-fluorophenyl)methyl]-3-N-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,6-dihydropyrazolo[4,3-c]pyridine-3,7-dicarboxamide |
| INCHI | 1S/C30H31FN6O4/c1-17-12-21(13-18(2)25(17)41-4)34-27(38)24-22-15-36(28(39)23-6-5-11-33-23)16-30(3,29(32)40)26(22)37(35-24)14-19-7-9-20(31)10-8-19/h5-13,33H,14-16H2,1-4H3,(H2,32,40)(H,34,38)/t30-/m0/s1 |
| InChi Key | DUCNNEYLFOQFSW-PMERELPUSA-N |
| Smiles | CC1=CC(=CC(=C1OC)C)NC(=O)C2=NN(C3=C2CN(CC3(C)C(=O)N)C(=O)C4=CC=CN4)CC5=CC=C(C=C5)F |
| Isomeric SMILES | CC1=CC(=CC(=C1OC)C)NC(=O)C2=NN(C3=C2CN(C[C@]3(C)C(=O)N)C(=O)C4=CC=CN4)CC5=CC=C(C=C5)F |
| PubChem CID | 91864701 |
| 分子量 | 558.6 |
| 溶解性 | DMSO : 100 mg/mL (179.02 mM; Need ultrasonic) |
|---|---|
| 分子量 | 558.600 g/mol |
| XLogP3 | 2.900 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 558.239 Da |
| 单同位素质量Monoisotopic Mass | 558.239 Da |
| 拓扑极表面积Topological Polar Surface Area | 135.000 Ų |
| 重原子数Heavy Atom Count | 41 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 967.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| RIDADR | NONHforallmodesoftransport |
|---|